Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: GSK 10.595, Moderna 0.145.
GSK vs Moderna: Revenue Comparison
GSK (GSK) and Moderna (MRNA) are peers in Vaccines. GSK reported revenue of $10.6B as of Q2 2026, compared with $145M for Moderna. GSK leads on revenue.
GSK's gross margin is 73.0% versus 35.9% for Moderna. GSK's net margin is 5.2% versus -539.3% for Moderna.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, GSK, Moderna.| Metric | GSK | Moderna |
|---|---|---|
| Market Cap | - | - |
| Revenue | $10.60B | $145.00M |
| Cost of Revenue | $2.85B | $93.00M |
| Gross Profit | $7.74B | $52.00M |
| Operating Income | $606.00M | $-815.00M |
| Net Income | $548.00M | $-782.00M |
| R&D Expense | $4.37B | $651.00M |
| Earnings Per Share | $0.28 | -$1.96 |
| Gross Margin | 73.0% | 35.9% |
| Operating Margin | 5.7% | -562.1% |
| Net Profit Margin | 5.2% | -539.3% |
| Free Cash Flow | $2.78B | $-563.00M |
| Cumulative Free Cash Flow | $157.21B | $7.37B |
| Operating Cash Flow | $3.19B | $-526.00M |
| Cash & Equivalents | $3.89B | $1.72B |